scholarly journals Regulation of the human cellular glutathione peroxidase gene during in vitro myeloid and monocytic differentiation

Blood ◽  
1994 ◽  
Vol 84 (11) ◽  
pp. 3902-3908 ◽  
Author(s):  
Q Shen ◽  
S Chada ◽  
C Whitney ◽  
PE Newburger

We have used the HL-60 and PLB-985 myeloid leukemia cell lines to examine the regulation of expression of the important intracellular antioxidant enzyme, glutathione peroxidase (GSH-Px), during phagocytic cell differentiation in vitro. Induction of differentiation along the monocytic pathway by phorbol ester results in an approximately twofold rise in enzyme activity and a parallel increase in the rate of 75Se incorporation into immunoprecipitable GSH-Px protein. Induction along the granulocytic pathway by dimethyl formamide (DMF) results in similar changes in steady-state enzyme levels and rates of GSH-Px protein synthesis. Steady-state levels of GSH-Px gene transcripts also increase more than twofold, approximately in parallel with the enzyme levels. Nuclear run-on transcription assays of GSH-Px mRNA synthesis show ratios of induced to uninduced transcript levels of 2.24 and 1.59 with phorbol myristate acetate (PMA) induction and DMF, respectively, in HL- 60 cells, and ratios of 1.34 and 3.46 with PMA and DMF, respectively, in PLB-985 cells. Half lives of GSH-Px mRNA are unchanged or slightly shorter after differentiation of HL-60 cells, and slightly longer after induction of PLB-985. Overall, the present studies show that GSH-Px activity rises during in vitro-induced monocytic or granulocytic differentiation of myeloid cell lines and that the increased expression of the cellular GSH-Px gene occurs through complex mechanisms that include transcriptional up-regulation. This pattern contrasts with the nearly complete cotranslational regulation of GSH-Px expression by exogenous selenium.

Blood ◽  
2009 ◽  
Vol 114 (22) ◽  
pp. 1458-1458
Author(s):  
SunHwa Hong ◽  
Alan D. Friedman

Abstract Abstract 1458 Poster Board I-481 Mice lacking C/EBPα have reduced granulocyte-monocyte progenitors, and C/EBPα plays a role in the maturation of GMP along the granulocyte or monocyte lineages. C/EBPα is a member of the bZIP family of transcription factors, dimerizing with itself or other C/EBP proteins via its leucine zipper (LZ) domain to bind palindromic DNA elements (e.g. ATTGCGCAAT, designated αα sites) via the adjacent basic region (BR). AP-1 proteins such as c-Fos and c-Jun represent a distinct bZIP subfamily that heterodimerize amongst themselves to bind AP-1 sites (e.g. TGACTCA, designated JJ sites) to also mediate monocytic differentiation in hematopoietic cell lines or transduced marrow cells. In addition, we previously demonstrated that C/EBPα or C/EBPβ can zipper with c-Jun, JunB, or c-Fos (Cai et al 2008). To accomplish this we employed hybrid proteins in which, for example, the c-Jun LZ was swapped in place of the C/EBPα LZ and binding to a C/EBP site was then assessed after expression in 293T cells. We also provided data suggesting that C/EBPα:c-Jun heterodimers bind preferentially to hybrid αJ sites (e.g. TGACGCAAT). To accomplish this we forced heterodimerization by replacing the LZ in C/EBPα with an acidic zipper containing multiple glutamic acid residues (LZE) and replaced the LZ in c-Jun with a basic zipper containing multiple lysines (LZK). We have now extended these initial findings in two ways. First, we demonstrate that the intact proteins, not only those containing artificial acid or basic leucine zippers, maintain binding site specificity. In particular, when expressed in 293T cells or when generated by coupled in vitro transcription/translation, C/EBPα alone preferentially binds an αα site whereas C/EBPα co-expressed with c-Jun prefers the αJ site. Neither C/EBPα alone nor C/EBPα:c-Jun bound a JJ site. Consistent with the weak affinity of C/EBPα for c-Jun, formation of sufficient C/EBPα:c-Jun heterodimers to allow detection of preferential binding to the αJ site required a 4:1 c-Jun:C/EBPα ratio, with input proteins normalized via a shared N-terminal myc tag. Super-shift assays confirmed that a single gel shift band contains both proteins under these conditions. Co-expression of c-Jun with c-Fos yielded complexes that bound JJ sites, but interestingly c-Jun:c-Fos bound αJ sites with even greater affinity. Second, we have used biotinylated αα and αJ oligonucleotides to demonstrate the presence of both endogenous C/EBPα:C/EBPα and C/EBPα:c-Jun complexes in myeloid cell lines. When 32Dcl3 cells are placed in G-CSF for 24 hrs to stimulate granulopoiesis, Western blotting indicates that C/EBPα levels are induced while c-Jun levels remain constant, and binding of C/EBPα to the αα biotin-oligo increases, likely reflecting the presence of endogenous C:EBPα homodimers, as no interaction of c-Jun with the αα probe was detected. Both endogenous C/EBPα and c-Jun interact the αJ biotin-oligo, suggesting binding by an endogenous C/EBPα:c-Jun complex, and binding of each of these proteins to this probe also increases upon G-CSF induction of C/EBPα. Further support for the presence of an endogenous C/EBPα:c-Jun complex comes from the observation that interaction of C/EBPα with the αJ oligo is several-fold stronger than with the αα oligo, before or after G-CSF addition, whereas gel shift assay results described above indicate that C/EBPα homodimers prefer the αα probe. We previously found that C/EBPαLZK:C/EBPαLZE homodimers favor granulopoiesis whereas C/EBPαLZK:c-JunLZE heterodimers favor monopoiesis of marrow progenitors (Cai et al 2008). In summary, new data indicate that when c-Jun is present in excess, co-expressed C/EBPα and c-Jun preferentially binds hybrid αJ site, and C/EBPα:c-Jun complexes are detected endogenously in myeloid cells. These new findings provide biochemical support for the idea that C/EBPα:AP-1 heterodimers bind novel DNA elements to help mediate monopoiesis, with C/EBPα:C/EBPα homodimers potentially favoring granulopoiesis. Our future focus will be to further define the cellular levels of endogenous C/EBP, AP-1, and C/EBP:AP-1 complexes in immature and mature monocytic and granulocytic cells and to elucidate the spectrum of genes these complexes bind and regulate during myelopoiesis. Disclosures No relevant conflicts of interest to declare.


Blood ◽  
2005 ◽  
Vol 105 (5) ◽  
pp. 2107-2114 ◽  
Author(s):  
Joachim Schwäble ◽  
Chunaram Choudhary ◽  
Christian Thiede ◽  
Lara Tickenbrock ◽  
Bülent Sargin ◽  
...  

AbstractActivating fetal liver tyrosine kinase 3 (Flt3) mutations represent the most common genetic aberrations in acute myeloid leukemia (AML). Most commonly, they occur as internal tandem duplications in the juxtamembrane domain (Flt3-ITD) that transform myeloid cells in vitro and in vivo and that induce aberrant signaling and biologic functions. We identified RGS2, a regulator of G-protein signaling, as a gene specifically repressed by Flt3-ITD. Here we demonstrate an important role of RGS2 in Flt3-ITD–mediated transformation. RGS2 was repressed after forced expression of activating Flt3 mutations in 2 myeloid cell lines (32Dcl3 and NB4). Furthermore, RGS2 was repressed in Flt3-mutation–positive AML cases in comparison to Flt3-mutation–negative cases, especially in Flt3-ITD–positive cases with a high ITD-to–wild-type (WT) ratio. Coexpression of RGS2 with Flt3-ITD inhibited Flt3-ITD–induced autonomous proliferation and clonal growth of 32D cells. RGS2 also inhibited Flt3-ITD–induced phosphorylation of Akt and glycogen synthase kinase β (Gsk3-β) without influencing signal transducer and activator of transcription 5 (STAT5) activation. In addition, RGS2 reinduced the expression of Flt3-ITD–repressed CCAAT/enhancer-binding protein α (c/EBPα) and antagonized the Flt3-ITD–induced differentiation block in 32D cells. Expression analyses in myeloid cell lines revealed induction of RGS2 during granulocytic but not during monocytic differentiation. Taken together, RGS2 is a novel mediator of myeloid differentiation, and its repression is an important event in Flt3-ITD–induced transformation.


1979 ◽  
Vol 149 (4) ◽  
pp. 969-974 ◽  
Author(s):  
S J Collins ◽  
F W Ruscetti ◽  
R E Gallagher ◽  
R C Gallo

The HL-60 human promyelocytic leukemia cell line can be induced to terminally differentiate to mature myeloid cells sharing a number of functional characteristics with normal granulocytes including response to chemoattractants, development of complement receptors, phagocytosis, superoxide production, and nitroblue tetrazolium dye reduction. Hence the Me2SO-induced HL-60 cells provide a unique in vitro model for studying various important aspects of human myeloid cell differentiation.


1995 ◽  
Vol 19 (10) ◽  
pp. 681-691 ◽  
Author(s):  
H.G. Drexler ◽  
H. Quentmeier ◽  
R.A.F. MacLeod ◽  
C.C. Uphoff ◽  
Z.-B. Hu

Author(s):  
Yudi Miao ◽  
Behnam Mahdavi ◽  
Mohammad Zangeneh

IntroductionThe present study investigated the anti-acute myeloid leukemia effects of Ziziphora clinopodides Lam leaf aqueous extract conjugated cadmium nanoparticles.Material and methodsTo synthesize CdNPs, Z. clinopodides aqueous extract was mixed with Cd(NO3)2 .4H2O. The characterization of the biosynthesized cadmium nanoparticles was carried out using many various techniques such as UV-Vis. and FT-IR spectroscopy, XRD, FE-SEM, and EDS.ResultsThe uniform spherical morphology of NPs was proved by FE-SEM images with NPs the average size of 26.78cnm. For investigating the antioxidant properties of Cd(NO3)2, Z. clinopodides, CdNPs, and Daunorubicin, the DPPH test was used. The cadmium nanoparticles inhibited half of the DPPH molecules in a concentration of 196 µg/mL. To survey the cytotoxicity and anti-acute myeloid leukemia effects of Cd(NO3)2, Z. clinopodides, CdNPs, and Daunorubicin, MTT assay was used on the human acute myeloid leukemia cell lines i.e., Murine C1498, 32D-FLT3-ITD, and Human HL-60/vcr. The IC50 of the cadmium nanoparticles was 168, 205, and 210 µg/mL against Murine C1498, 32D-FLT3-ITD, and Human HL-60/vcr cell lines, respectively. In the part of in vivo study, DMBA was used for inducing acute myeloid leukemia in mice. CdNPs similar to daunorubicin ameliorated significantly (p≤0.01) the biochemical, inflammatory, RBC, WBC, platelet, stereological, histopathological, and cellular-molecular parameters compared to the other groups.ConclusionsAs mentioned, the cadmium nanoparticles had significant anti-acute myeloid leukemia effects. After approving the above results in the clinical trial studies, these cadmium nanoparticles can be used as a chemotherapeutic drug to treat acute myeloid leukemia in humans.


1996 ◽  
Vol 16 (2) ◽  
pp. 487-495 ◽  
Author(s):  
S Soddu ◽  
G Blandino ◽  
R Scardigli ◽  
R Martinelli ◽  
M G Rizzo ◽  
...  

Expression of exogenous wild-type (wt) p53 in different leukemia cell lines can induce growth arrest, apoptotic cell death, or cell differentiation. The hematopoietic cell lines that have been used so far to study wt p53 functions have in common the characteristic of not expressing endogenous p53. However, the mechanisms involved in the transformation of these cells are different, and the cells are at different stages of tumor progression. It can be postulated that each type of neoplastic cell offers a particular environment in which p53 might generate different effects. To test this hypothesis, we introduced individual oncogenes into untransformed, interleukin-3 (IL-3)-dependent myeloid precursor 32D cells to have a single transforming agent at a time. The effects induced by wt p53 overexpression were subsequently evaluated in each oncogene-expressing 32D derivative. We found that in not fully transformed, v-ras-expressing 32D cells, as already shown for the parental 32D cells, overexpression of the wt p53 gene caused no phenotypic changes and no reduction of the proliferative rate as long as the cells were maintained in their normal culture conditions (presence of IL-3 and serum). An accelerated rate of apoptosis was observed after IL-3 withdrawal. In contrast, in transformed, IL-3-independent 32D cells, wt p53 overexpression induced different effects. The v-abl-transformed cells manifested a reduction in growth rate, while the v-src-transformed cells underwent monocytic differentiation. These results show that the phenotype effects of wt p53 action(s) can vary as a function of the cellular environment.


Nutrients ◽  
2019 ◽  
Vol 11 (11) ◽  
pp. 2808 ◽  
Author(s):  
Ghanem ◽  
Zouein ◽  
Mohamad ◽  
Hodroj ◽  
Haykal ◽  
...  

Acute myeloid leukemia (AML) is a blood cancer characterized by the formation of faulty defective myelogenous cells with morphological heterogeneity and cytogenic aberrations leading to a loss of their function. In an attempt to find an effective and safe AML treatment, vitamin E derivatives, including tocopherols were considered as potential anti-tumor compounds. Recently, other isoforms of vitamin E, namely tocotrienols have been proposed as potential potent anti-cancerous agents, displaying promising therapeutic effects in different cancer types. In this study we evaluated the anti-cancerous effects of γ-tocotrienol, on AML cell lines in vitro. For this purpose, AML cell lines incubated with γ-tocotrienol were examined for their viability, cell cycle status, apoptotic cell death, DNA fragmentation, production of reactive oxygen species and expression of proapoptotic proteins. Our results showed that γ-tocotrienol exhibits time and dose-dependent anti-proliferative, pro-apoptotic and antioxidant effects on U937 and KG-1 cell lines, through the upregulation of proteins involved in the intrinsic apoptotic pathway.


Leukemia ◽  
2002 ◽  
Vol 16 (4) ◽  
pp. 683-692 ◽  
Author(s):  
MB Miranda ◽  
TF McGuire ◽  
DE Johnson

Blood ◽  
1983 ◽  
Vol 61 (1) ◽  
pp. 171-179 ◽  
Author(s):  
D Ferrero ◽  
S Pessano ◽  
GL Pagliardi ◽  
G Rovera

Abstract The surface changes occurring in three acute myeloid leukemia cell lines (HL60, ML3, and KG1) induced to differentiate by a variety of agents (dimethylsulfoxide, retinoic acid, 12-O-tetradecanoylphorbol-13- acetate, and factors present in lymphocyte conditioned medium) were probed using monoclonal antibodies that are differentiation stage- and lineage-specific. In all cases, the differentiated phenotype was defective and varied with the inducing agent and the cell line used. HL60 proved to be the most sensitive to the effect of the inducers. Retinoic acid was better than DMSO, and TPA was better than the medium factors in the ability to induce granulocytic and monocytic differentiation, respectively, in HL60 cells. These findings indicate that the differentiation block in acute myeloid leukemias is heterogeneous and that each cell line has different phenotypic characteristics that are responsible for the extent of differentiation obtained with a given inducer. These results also suggest that the extent of the differentiation response in vitro may be improved by the use of more suitable inducers for each specific leukemic line.


Blood ◽  
1993 ◽  
Vol 81 (4) ◽  
pp. 889-893 ◽  
Author(s):  
S Kobayashi ◽  
M Teramura ◽  
I Sugawara ◽  
K Oshimi ◽  
H Mizoguchi

Abstract The cytokine interleukin-11 (IL-11) promotes normal human megakaryocytopoiesis in vitro. However, its role in abnormal megakaryocytopoiesis is not well known. Accordingly, we studied its effects on human megakaryoblastic cell lines CMK and Meg-J. IL-11 stimulated the proliferation of CMK and Meg-J in a dose-dependent manner with maximal growth being achieved at the concentration of 50 and 500 ng/mL, respectively. The growth of the cells was inhibited by anti-IL-11 antibody and IL-11 antisense oligonucleotides. IL-11 transcripts were detected in these two cell lines using a reverse transcriptase-polymerase chain reaction assay. These findings indicate that IL-11 might be an autocrine growth factor for megakaryoblastic cells. IL-11 transcripts also existed in other leukemia cell lines: HL- 60, U937, and K562. However, the growth of these cells was not stimulated by IL-11, and was not inhibited by IL-11 antisense oligonucleotides. These results suggested that IL-11 might regulate malignant cells of the megakaryocytic lineage, in part by an autocrine loop.


Sign in / Sign up

Export Citation Format

Share Document